Contact Us

Author: Anneka Baxter

Categories
Resources

Download: Narrative Contamination: GLP-1 Indication Strategy

Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future, is a strategic resource exploring how U.S. drug pricing could change if new international reference pricing (IRP) policies take hold. Using a sample portfolio, we model potential impacts across multiple scenarios to help market access teams prepare for what may come next.

Understanding the Evolving IRP Landscape

A May 2025 Executive Order has reignited the debate around MFN pricing, with the potential to tie US drug prices to what other high-income countries pay. This isn’t just policy speculation, it’s a regulatory shift that could fundamentally alter pharmaceutical economics worldwide.

The concept isn’t new. Previous MFN proposals faced significant legal challenges, but the current political climate and growing pressure on drug prices have brought International Reference Pricing (IRP) back into sharp focus. The difference now? The potential for implementation feels more real than ever.

For market access teams, this represents uncharted territory. How do you prepare for a policy that could reshape everything from launch sequencing to pricing strategies? How do you model impacts when the implementation details remain unclear?

Hear from the experts behind Access Infinity

Access Infinity’sinsights, taken from years of working with top-tier pharma companies and deep regulatory analysis, paint a clearer picture of what IRP implementation could mean for the industry. Our experts break down the May 2025 Executive Order and modelled its potential impacts across different implementation pathways.

What the analysis will cover

The analysis addresses some of the most pressing questions facing market access teams today, including:

  • Breaking down the executive order and its implications
  • Two critical scenarios for IRP implementation
  • Real portfolio impact modelling with patient cost analysis
  • Strategic responses for manufacturers and payers
  • Launch sequencing strategies to protect pricing power
  • Long-term implications for global pharmaceutical markets

Why scenario planning matters now

While regulatory uncertainty has always been part of pharmaceutical strategy, the potential for International Reference Pricing and MFN policy implementation represents a paradigm shift that demands immediate attention. So how can market access teams prepare for multiple outcomes and position themselves strategically?

Historically, while teams have planned for incremental policy changes, MFN pricing could fundamentally alter the economics of pharmaceutical innovation. Our new analysis showcases exactly why scenario-based planning is essential, helping teams prepare for disruption while identifying opportunities within regulatory change.

The analysis reveals that smart strategic positioning today could mean the difference between protecting market position and facing significant revenue erosion. From launch sequencing tactics to pricing optimisation strategies, there has never been a more crucial time to think ahead of regulatory change.

Likewise, understanding both the direct-to-consumer and channel disruption scenarios gives market access teams the competitive advantage they need. This analysis shows how to navigate uncertainty while maintaining strategic flexibility for whatever emerges.

Download the analysis today

‘Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future’ is essential reading for market access teams that want to stay ahead of regulatory change. It comes as just one of many expert resources from Access Infinity, including our ‘Market Access Matters’ podcast. You can also find out more in our on-demand webinars.

Gain deeper insights and plan for an uncertain but strategic future. Fill out the form below to receive your copy.

Download the resource

Categories
Webinars

Faster. Sharper. Smarter. Navigating the new era of market access.

Categories
Blog

GKV-BStabG is now law: Germany’s pharma rebate rises to 15.5% from January 2027

The Bundestag passed the GKV-BStabG on 10 July 2026, fixing the manufacturer rebate at 15.5% from 1 January 2027 with no phase-in. Here’s what changed between the draft and the final law, and what to do before budgets lock.

Germany’s GKV-BStabG (Beitragssatzstabilisierungsgesetz) cleared the Bundestag 319 to 286 on 10 July 2026, and the Bundesrat the same afternoon. The core pharma provisions take effect on 1 January 2027, with a handful of measures, including the removal of AMNOG price guardrails and the abolition of the combination discount, live from the day after promulgation in the Federal Law Gazette.

The final law replaces the draft’s open-ended dynamic rebate formula with a fixed rate. The manufacturer rebate rises from 7% to 15.5%, applied in full from day one, with no transitional period and no fixed expiry date.

What changed between the April draft and the final law

The manufacturer rebate was the most contested provision, and it changed the most. The April draft proposed a dynamic, formula-driven rebate that industry modelled at close to 20% by 2030. The Health Committee struck that formula and replaced it with a flat additional 8.5 percentage points on top of the existing 7% base, taking the total to 15.5% from 1 January 2027.

Two other provisions were tightened in committee: the volume-based fallback (scale factor up 50%) and the vaccine category rebate (raised from 7% to 9%, a stacked total of around 16%, plus a price freeze to 2030). The selective tendering pilot for patented drugs in five therapeutic classes and the combination discount abolition passed largely as drafted, as did the price moratorium extension to 31 December 2030.

Read the full analysis

 

Our full whitepaper covers all seven provisions as adopted against the April draft, the two positive changes for industry, portfolio-level guidance by company type and product type, the European price corridor implications for internationally referenced products, and a scenario-by-scenario action plan with dates through 2027.

Download the whitepaper

 

This blog is prepared by Access Infinity for informational purposes. All provisions described reflect the GKV-BStabG as passed on 10 July 2026 and stakeholder analysis current as of 23 July 2026. The Federal Law Gazette publication was pending at time of writing. This content does not constitute legal or financial advice.

Frequently asked questions (FAQs)

The rebate rises from 7% to 15.5% of the ex-VAT list price, effective 1 January 2027. This replaces the dynamic formula proposed in the April draft.

The 15.5% rebate and the vaccine measures apply from 1 January 2027. The removal of AMNOG price guardrails, the tendering pilot and the combination discount abolition take effect the day after the law is published in the Federal Law Gazette.

No. Unlike the April draft, which proposed a phased start at 10.5% for the first half of 2027, the final law applies the full 15.5% from day one, with no ramp-up period.

Biosimilars and their reference biologics are exempt. New active substances launching from 2027 can also qualify for a location-clause exemption if at least 5% of clinical trial participants are enrolled at German sites; this runs for three years and is renewable. Beyond the formal exemptions, the law leaves one further route open, known as supersession. It is not an exemption, but it can remove the additional 8.5 points where the reimbursement price is agreed on the right terms.

About the authors:
Brett Gardiner

Brett is a Senior Partner at Access Infinity and brings a unique combination of clinical and academic expertise in immunology and genetics to his role in pricing and market access. He possesses a proven track record of success, managing and contributing to the development of pricing and reimbursement strategies for over 200 biopharmaceuticals, vaccines, and medical devices across all product life cycle stages.

Emily Hall

Emily is an Associate Director at Access Infinity. Her consulting experience focusses on pricing and access strategy across diverse disease areas and global markets. She has led multiple projects involving extensive secondary, primary and quantitative research to support clients determine pricing and access potential, clinical trial design and launch sequencing for early and late-stage assets. 

Categories
Resources

Download: GKV-BStabG is now law:  What changed and what to do next

Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future, is a strategic resource exploring how U.S. drug pricing could change if new international reference pricing (IRP) policies take hold. Using a sample portfolio, we model potential impacts across multiple scenarios to help market access teams prepare for what may come next.

Understanding the Evolving IRP Landscape

A May 2025 Executive Order has reignited the debate around MFN pricing, with the potential to tie US drug prices to what other high-income countries pay. This isn’t just policy speculation, it’s a regulatory shift that could fundamentally alter pharmaceutical economics worldwide.

The concept isn’t new. Previous MFN proposals faced significant legal challenges, but the current political climate and growing pressure on drug prices have brought International Reference Pricing (IRP) back into sharp focus. The difference now? The potential for implementation feels more real than ever.

For market access teams, this represents uncharted territory. How do you prepare for a policy that could reshape everything from launch sequencing to pricing strategies? How do you model impacts when the implementation details remain unclear?

Hear from the experts behind Access Infinity

Access Infinity’sinsights, taken from years of working with top-tier pharma companies and deep regulatory analysis, paint a clearer picture of what IRP implementation could mean for the industry. Our experts break down the May 2025 Executive Order and modelled its potential impacts across different implementation pathways.

What the analysis will cover

The analysis addresses some of the most pressing questions facing market access teams today, including:

  • Breaking down the executive order and its implications
  • Two critical scenarios for IRP implementation
  • Real portfolio impact modelling with patient cost analysis
  • Strategic responses for manufacturers and payers
  • Launch sequencing strategies to protect pricing power
  • Long-term implications for global pharmaceutical markets

Why scenario planning matters now

While regulatory uncertainty has always been part of pharmaceutical strategy, the potential for International Reference Pricing and MFN policy implementation represents a paradigm shift that demands immediate attention. So how can market access teams prepare for multiple outcomes and position themselves strategically?

Historically, while teams have planned for incremental policy changes, MFN pricing could fundamentally alter the economics of pharmaceutical innovation. Our new analysis showcases exactly why scenario-based planning is essential, helping teams prepare for disruption while identifying opportunities within regulatory change.

The analysis reveals that smart strategic positioning today could mean the difference between protecting market position and facing significant revenue erosion. From launch sequencing tactics to pricing optimisation strategies, there has never been a more crucial time to think ahead of regulatory change.

Likewise, understanding both the direct-to-consumer and channel disruption scenarios gives market access teams the competitive advantage they need. This analysis shows how to navigate uncertainty while maintaining strategic flexibility for whatever emerges.

Download the analysis today

‘Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future’ is essential reading for market access teams that want to stay ahead of regulatory change. It comes as just one of many expert resources from Access Infinity, including our ‘Market Access Matters’ podcast. You can also find out more in our on-demand webinars.

Gain deeper insights and plan for an uncertain but strategic future. Fill out the form below to receive your copy.

Download the resource

Categories
News

Access Infinity Launches Next-Generation Nuro Platform

New platform gives market access teams the workspace, intelligence and global data to move faster from insight to strategy.

LONDON, UK – 13th July 2026 – Access Infinity today announced the next generation of Nuro™, its market access strategy platform. The new Nuro moves beyond intelligence to become a fully integrated operating environment. It combines the comprehensive HTA, pricing, regulatory and pipeline intelligence it has always been known for with new AI-powered analysis, collaboration, and strategic planning tools, all in one place. 

The new platform addresses a persistent challenge for market access teams: powerful intelligence exists, but it remains scattered across disconnected spreadsheets, databases, slide decks, and shared folders. Nuro unifies insight and action in a single platform. 

Commenting on this latest evolution of the platform, Thomas Gilboy, Product Owner at Access Infinity, said: 

"What began as a powerful intelligence platform is now the place where market access strategy gets built. Teams can develop project workspaces, generate competitor landscapes, compare TPP scenarios, and collaborate with colleagues - all within one space. That fundamentally changes how market access teams develop and execute strategy."
Thomas Gilboy
Product Owner

What’s new 

Each user now has a dedicated project space within Nuro, structured around their brands, competitors and disease areas. Teams can share workspaces, save analysis, generate new charts and insights, add their own thoughts via notes, and collaborate directly with colleagues, creating a living record of strategic thinking.  

A new AI layer enables teams to ask deeper strategic questions grounded in their project context. For example, “What is the best defensive strategy against a payer critique of a new long-acting injectable within our space?” Responses are anchored in Nuro’s data and the team’s own project history, not generic outputs. 

Teams can also save, assess, and compare Target Product Profiles (TPPs) against project insights. This is a more advanced and flexible evolution of the existing Virtual Payer Panel, enabling structured side-by-side evaluation of strategic options with evidence drawn directly from the platform. 

Related resources:  

For more information about Nuro, please visit: accessinfinity.com/nuro  

To see Nuro in action, get in touch on accessinfinity.com/nuro-demo-request/ 

About Access Infinity 

Founded in 2014, Access Infinity helps pharmaceutical companies launch and price their products more effectively by combining deep strategic consulting expertise with digital platforms purpose-built for market access and HEOR teams. The company’s experienced consultants work closely with global through to local teams to shape launch strategies, optimise pricing and access, and navigate complex policy landscapes. 

Access Infinity’s core digital solutions – Access Hub, Evidence Hub and Nuro – streamline everything from launch tracking and evidence planning to pricing strategy, enabling faster, smarter, and more coordinated decision-making across the product lifecycle. With offices in London, Manchester and Hyderabad, Access Infinity’s clients include many of the pharmaceutical industry’s most influential companies including AstraZeneca, GSK, J&J, MSD, and Pfizer. 

For media enquiries, please contact:  

Email: louise@accessinfinity.com  

Tel: +44 (0)20 4583 5450

Accessinfinity.com   

Categories
Blog

Measuring payer engagement impact on market access KPIs

How local implementation strategies and payer engagement quality can influence time to access, breadth of access, and price – and what pharmaceutical companies can do about it.

A successful market access launch is typically measured against three KPIs: time to access, breadth of access, and price. But these metrics only tell part of the story. The hidden drivers – payer perception, engagement quality, and message recall – can directly influence whether those KPIs are ever met. Without a structured feedback loop to capture these softer signals, country teams are left making tactical decisions in the dark.

The traditional access triangle: necessary but not sufficient

When a pharmaceutical company launches a new product or indication, global teams set a market access strategy anchored in a familiar framework: the Access Triangle. Regional and local teams are then responsible for translating that global strategy into tactical, actionable implementation plans.

The three KPIs are:

  • Time to access – how quickly is reimbursement achieved?
  • Breadth of access – which patients or geographies are covered?
  • Price – was the manufacturer’s target price achieved or maintained

The outcome of these KPIs is black and white – they are either met or not met. If they are met, everyone is happy. If not, there is rarely a structured feedback loop to help country teams understand the subjective drivers behind that shortfall. In most cases, at least one of those three KPIs will require some degree of compromise – but without understanding why, the same mistakes are repeated.

The hidden obstacles influencing market access outcomes

Beyond clinical evidence and value dossiers, there are more subtle, psychological and relational factors at play. These include:

  • Payer perceptions of the manufacturer – a single negative engagement in the past, or a perception of low trustworthiness, can unconsciously colour reimbursement decisions.
  • Frequency and quality of payer communications – too frequent, and payers feel overwhelmed; too infrequent, and the manufacturer risks being forgotten.
  • Channel appropriateness – a cold call to a busy hospital pharmacist may be disruptive and counterproductive. The right message in the wrong channel can undermine an otherwise strong engagement strategy.
  • Message recall and competitor benchmarking – if payers cannot recall your product’s key value messages but can recall a competitor’s, your product is not top of mind when reimbursement decisions are made.
  • Corporate reputation and portfolio perception – do payers view your company as trustworthy? Do they consider your portfolio worthwhile? These broader perceptions feed indirectly into how individual products are received.
“If the overall engagement strategy isn’t relevant for the stakeholder - if the channel of communication isn’t appropriate, or the frequency of contact isn’t appropriate - then that could tarnish the entire customer relationship and consequently impact the outcome of a reimbursement decision, unconsciously.”
Megan O'Brien
Associate Director, Access Infinity

How market access teams currently engage with payers

Most access teams today use some form of omni-channel engagement. The most common channels are:

  • Face-to-face meetings – still preferred in many markets and cultural contexts, particularly for high-stakes conversations.
  • Phone calls – useful for follow-up and relationship maintenance, though timing and context matter.
  • Email – often the preferred first point of contact, particularly for stakeholders with busy clinical schedules.
  • Digital and indirect channels – including LinkedIn, targeted advertising, and webinars, which are growing in relevance post-pandemic.

The mix of channels used, and how they are sequenced, can significantly affect the quality of the payer relationship. Yet most companies do not systematically measure whether their chosen engagement approach is actually working.

Why the current feedback loop is not enough

There is a traditional feedback loop in market access: value message testing, health technology assessment outcomes, and reimbursement decisions. These are valuable, but they are lagging indicators. They tell you what happened – not why, and not what you could do differently.

What is largely missing is a structured mechanism to capture:

  • How payers perceive the manufacturer as a partner, not just a supplier
  • Whether communications are seen as relevant, timely, and trustworthy
  • How the company’s engagement compares to that of competitors
  • Whether payers can recall the brand’s key value messages

Without this insight, country teams are left making tactical decisions in the dark – unable to course-correct before a reimbursement outcome crystallises.

How to start measuring payer perception: a practical approach

The most effective way to build this missing feedback loop is through impartial, structured primary research – commissioned from a third party to ensure objectivity.

Step 1:
Define what you want
to measure

  • Corporate perception: trustworthiness, social responsibility, portfolio value
  • Engagement quality: frequency, relevance, channel appropriateness
  • Message recall: can payers name your product’s key value claims unprompted?
  • Competitive benchmarking: how do you compare to other manufacturers?

Step 2:
Select the right research methodology

  • Qualitative interviews with payer decision-makers to uncover nuanced perceptions
  • Quantitative surveys to benchmark performance across markets and against competitors
  • Advisory boards facilitated by a neutral third party to capture candid feedback

Step 3:
Analyse findings against KPI performance

  • Overlay perception data with access outcomes by country or region
  • Identify correlations between low payer trust scores and delays in time to access
  • Use findings to prioritise where engagement strategy changes will have the biggest impact

Step 4:
Connect insights to tools
like Access Hub

  • Platforms like Access Hub already track reimbursement status and price across markets
  • Combining this with perception data creates a richer picture of what is driving outcomes – not just what the outcomes are
  • This enables global teams to learn from high-performing countries and support those that are struggling

Hear from the experts at Access Infinity

Listen to the Market Access Matters podcast with Megan O’Brien, Associate Director at Access Infinity, to hear more about how payer perception shapes market access outcomes – and what teams can do about it.  

Listen now.

Frequently Asked Questions

Payer perception refers to how healthcare payers – such as national reimbursement bodies, hospital formulary committees, or regional health authorities – view a pharmaceutical manufacturer and its products. Perception influences trust, which in turn shapes how receptive payers are to value messages and reimbursement submissions. A negative perception, even from a single poor engagement experience, can unconsciously bias decision-making.

Value message testing evaluates whether specific clinical or economic claims land as intended – are they clear, credible, and relevant? Payer perception research goes further, examining the broader relationship between the manufacturer and the payer: trust, engagement quality, communication frequency, channel preference, and competitive standing. Both are important, but most companies do the former without ever doing the latter.

Ideally, perception research should be conducted at key milestones: before a launch to establish a baseline, at the time of HTA submission, and post-launch to identify areas for improvement. In competitive therapy areas, annual (or more frequent) benchmarking may be appropriate to track shifts over time.

Yes, and this is one of the key benefits. Global and regional teams can use perception data to identify which countries have the strongest payer relationships and what they are doing differently – then share those best practices with markets that are underperforming. Connecting this data to a tool like Access Hub makes it even more actionable.

Conclusion

Meeting the Access Triangle KPIs remains the ultimate measure of market access success. But relying solely on black-and-white outcomes – without understanding the subjective drivers behind them – leaves teams without the insight they need to improve. By building a structured feedback loop around payer perception, engagement quality, and message recollection, pharmaceutical companies can provide local teams with the tools to engage more effectively, communicate more memorably, and ultimately achieve better reimbursement outcomes.

Want to find out how your payer engagement strategy measures up?

At Access Infinity, we help pharma companies understand the hidden drivers behind their market access outcomes, from payer perception research to actionable engagement strategies.

Get in touch with our team here to discuss your specific needs.

About the author

Megan is an Associate Director at Access Infinity with nearly 15 years of pharmaceutical consultancy experience, specialising in pricing and market access, real-world evidence generation, and business intelligence. She has led strategic partnerships for major pharmaceutical clients and offers deep expertise into the world of payers and market access strategy across global markets. Megan has also designed and delivered single- and multi-sponsor non-interventional RWE studies, delivering pragmatic, evidence-based solutions to address complex market access challenges designed to meet the needs of payers.

If you have a question or a project in mind, get in touch with Megan by emailing megan@accessinfinity.com or via our contact us page.

Categories
Podcasts

Understanding Payer Perceptions with Megan O’Brien

Add Your Heading Text Here

Categories
Webinars

Rare disease pricing in 2026 and beyond

Categories
Resources

Download: Germany’s GKV-BStabG Reform: What It Really Means for Pharma

Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future, is a strategic resource exploring how U.S. drug pricing could change if new international reference pricing (IRP) policies take hold. Using a sample portfolio, we model potential impacts across multiple scenarios to help market access teams prepare for what may come next.

Understanding the Evolving IRP Landscape

A May 2025 Executive Order has reignited the debate around MFN pricing, with the potential to tie US drug prices to what other high-income countries pay. This isn’t just policy speculation, it’s a regulatory shift that could fundamentally alter pharmaceutical economics worldwide.

The concept isn’t new. Previous MFN proposals faced significant legal challenges, but the current political climate and growing pressure on drug prices have brought International Reference Pricing (IRP) back into sharp focus. The difference now? The potential for implementation feels more real than ever.

For market access teams, this represents uncharted territory. How do you prepare for a policy that could reshape everything from launch sequencing to pricing strategies? How do you model impacts when the implementation details remain unclear?

Hear from the experts behind Access Infinity

Access Infinity’sinsights, taken from years of working with top-tier pharma companies and deep regulatory analysis, paint a clearer picture of what IRP implementation could mean for the industry. Our experts break down the May 2025 Executive Order and modelled its potential impacts across different implementation pathways.

What the analysis will cover

The analysis addresses some of the most pressing questions facing market access teams today, including:

  • Breaking down the executive order and its implications
  • Two critical scenarios for IRP implementation
  • Real portfolio impact modelling with patient cost analysis
  • Strategic responses for manufacturers and payers
  • Launch sequencing strategies to protect pricing power
  • Long-term implications for global pharmaceutical markets

Why scenario planning matters now

While regulatory uncertainty has always been part of pharmaceutical strategy, the potential for International Reference Pricing and MFN policy implementation represents a paradigm shift that demands immediate attention. So how can market access teams prepare for multiple outcomes and position themselves strategically?

Historically, while teams have planned for incremental policy changes, MFN pricing could fundamentally alter the economics of pharmaceutical innovation. Our new analysis showcases exactly why scenario-based planning is essential, helping teams prepare for disruption while identifying opportunities within regulatory change.

The analysis reveals that smart strategic positioning today could mean the difference between protecting market position and facing significant revenue erosion. From launch sequencing tactics to pricing optimisation strategies, there has never been a more crucial time to think ahead of regulatory change.

Likewise, understanding both the direct-to-consumer and channel disruption scenarios gives market access teams the competitive advantage they need. This analysis shows how to navigate uncertainty while maintaining strategic flexibility for whatever emerges.

Download the analysis today

‘Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future’ is essential reading for market access teams that want to stay ahead of regulatory change. It comes as just one of many expert resources from Access Infinity, including our ‘Market Access Matters’ podcast. You can also find out more in our on-demand webinars.

Gain deeper insights and plan for an uncertain but strategic future. Fill out the form below to receive your copy.

Download the resource

Categories
Events

World EPA Congress 2027

World EPA Congress

  • 2nd - 3rd March
  • RAI Congress Centre, Amsterdam

Let’s meet in Amsterdam

Join us at the RAI Congress Centre between 2nd-3rd March where we’ll be sharing the latest insights and innovations from the Access Infinity team on industry hot topics.

Find out more
Join us on Day 1, 12:20 PM to hear:

From data to decisions: a framework for becoming the hero of your market access story

Behind every successful launch is a clear, compelling story and a team equipped to lead it. In this session, David McConkey explores a practical framework that helps Global access leaders decode reimbursement challenges, identify what truly drives performance, and communicate their impact with confidence. Learn how to transform fragmented data into a unified narrative that positions your team as the hero guiding the organisation toward faster access.

David McConkey

Partner – Digital Product Lead

David has approx. 20 years of work experience in the pharmaceutical industry. David has led on HTA negotiations in the UK and Ireland, developed health economic materials, generated launch and pricing strategies for novel drugs, led on cross country affiliate engagement, presented to leadership all the way up to C-Suite and more.

Join us on Day 1, 2:45 PM for our panel discussion:

AI in market access: knowing when it’s the hero (and when it isn’t)

Moderator:  Thomas Gilboy, Product Owner, Access Infinity

Panellists:  

  • Aodan Tynan, Head of Access Implementation, Pricing & Value Demonstration, Astellas

  • Marlene Gyldmark, EU HTA lead, BeOne Medicines

  • Sandeep Kiri, Global Head, Health Economic Evidence, UCB

  • Dilip Patel, SVP Global Pricing and Market Access, Autolus

AI isn’t the only superpower available to market access teams, and sometimes it is not the one you need. In this panel, leaders will discuss how they evaluate problems first, then select the most effective solution, whether that is AI, automation, analytics, process redesign, or human expertise. Lead by Access Infinity’s Product Owner, Tom Gilboy, this session explores common misconceptions about AI’s fit in market access, highlight where alternative tools or approaches outperform AI, and offer practical guidance on building a smarter and more balanced capability set across global and local teams.

Meet Access Infinity's digital team

Keshav Nagaraja

Managing Director

Robert Buckley

Associate Director, Business Development

Russ Leslie

Head of Sales

Louise Bennett

Head of Marketing

 

THOMAS GILBOY​

Product Owner

Louise Bennett

Head of Marketing

 

Ahmed Edathodu

Founding Director

Isabel Rubio

Director

Robert Buckley

Senior Business Development Manager

Thomas Gilboy

Product Owner

Margaret Labban

Product Manager

Best practices in estimating pipeline product prices for early market access teams

It goes without saying that analogues are a great choice for robust evidence because they tell us what’s historically happened to products in similar situations. Of course, there is no perfect analogue that 100% meets your own product, so how do you choose which ones to analyse and review?
There’s much to consider and a lot at stake, not to mention the time pressures you’re facing to answer complex questions, at pace.
So how can early market access professionals take a holistic approach to finding the right analogues in the right time frame?
Our Product Owner Thomas Gilboy explores this at EPA Congress, taking a deeper dive into:
· The analogue analysis challenges faced by today’s early market access teams[LB1]
· How to produce more accurate analysis and evidence to support a product’s launch strategy
· How to pick up the pace of analogue analysis [LB2] so that you can respond rapidly and accurately to enquiries from the [launch?] team

Let’s meet in person

The World EPA Congress 2022 is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Amsterdam.

Meet us at Booth 20.

LET’S BLOCK A TIME

About Access Infinity

Access Infinity is the world leader of digital transformation in the Pharma Industry. We are a trusted provider of digital platforms and consulting services to leading pharma companies

MORE ABOUT US

We come in two flavours

Consulting

The critical support you need to develop a successful value assessment and launch strategy.

  • Pricing and launch strategy
  • Evidence gap analysis
  • Multi-indication price optimisation
Digital products

Time-saving digital solutions that help you launch your brand to the right patients, at the right price, at the right time.

  • Access Hub - Track KPIs
  • Nuro - HTA & pricing intelligence
  • Evidence Hub - Evidence generation

We look forward to meeting you

World EPA Congress is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Amsterdam.

Contact us

Copyright All Rights Reserved
Access Infinity 2025

Get in touch

contact@accessinfinity.com

Uncommon Holborn
81-87 High Holborn,
London
WC1V 6DF

Consulting

Pricing and launch strategy
Evidence gap analysis
Multi-indication price optimisation
Fast due diligence
Analogue analysis
Revenue optimisation

Products

Nuro
Access Hub
Evidence Hub

Resources

Blogs
Webinar
Podcasts

About us

Company information
Leadership
Events
News

Copyright Notice | Terms of Use | Privacy Policy